Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Social Networks
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. Hosting Providers
  13. CDN Services

We began analyzing https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.107.724880, but it redirected us to https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.107.724880. The analysis below is for the second page.

Title[redir]:
Effect of Ranolazine, an Antianginal Agent With Novel Electrophysiological Properties, on the Incidence of Arrhythmias in Patients With Non–ST-Segment–Elevation Acute Coronary Syndrome | Circulation
Description:
Background— Ranolazine, a piperazine derivative, reduces ischemia via inhibition of the late phase of the inward sodium current (late INa) during cardiac repolarization, with a consequent reduction in intracellular sodium and calcium overload. Increased intracellular calcium leads to both mechanical dysfunction and electric instability. Ranolazine reduces proarrhythmic substrate and triggers such as early afterdepolarization in experimental models. However, the potential antiarrhythmic actions of ranolazine have yet to be demonstrated in humans. Methods and Results— The Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST-Elevation Acute Coronary Syndrome (MERLIN)–Thrombolysis in Myocardial Infarction (TIMI) 36 (MERLIN-TIMI 36) trial randomized 6560 patients hospitalized with a non–ST-elevation acute coronary syndrome to ranolazine or placebo in addition to standard therapy. Continuous ECG (Holter) recording was performed for the first 7 days after randomization. A prespecified set of arrhythmias were evaluated by a core laboratory blinded to treatment and outcomes. Of the 6560 patients in MERLIN-TIMI 36, 6351 (97%) had continuous ECG recordings that could be evaluated for arrhythmia analysis. Treatment with ranolazine resulted in significantly lower incidences of arrhythmias. Specifically, fewer patients had an episode of ventricular tachycardia lasting ≥8 beats (166 [5.3%] versus 265 [8.3%]; P<0.001), supraventricular tachycardia (1413 [44.7%] versus 1752 [55.0%]; P<0.001), or new-onset atrial fibrillation (55 [1.7%] versus 75 [2.4%]; P=0.08). In addition, pauses ≥3 seconds were less frequent with ranolazine (97 [3.1%] versus 136 [4.3%]; P=0.01). Conclusions— Ranolazine, an inhibitor of late INa, appears to have antiarrhythmic effects as assessed by continuous ECG monitoring of patients in the first week after admission for acute coronary syndrome. Studies specifically designed to evaluate the potential role of ranolazine as an antiarrhythmic agent are warranted.

Matching Content Categories {📚}

  • Health & Fitness
  • Education
  • Insurance

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🏙️ Massive Traffic: 50M - 100M visitors per month


Based on our best estimate, this website will receive around 76,079,999 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We can't tell how the site generates income.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Doi.org could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

ranolazine, patients, ventricular, tachycardia, cardiovascular, medical, crossref, beats, division, arrhythmias, coronary, cecg, netherlands, cardiac, timi, lasting, heart, potential, therapeutics, pubmed, trial, circulation, antiarrhythmic, treatment, ischemia, clinical, late, placebo, google, scholar, view, study, group, acute, merlintimi, ina, death, medicine, article, incidence, effects, effect, agent, myocardial, mass, brigham, womens, hospital, boston, center,

Topics {✒️}

aha/asa scientific statements acc/aha/esc 2006 guidelines cochran-mantel-haenszel test stratifying reverse-mode sodium-calcium exchange high-risk clinical features american heart association acute coronary syndromes supplements download pdf acute coronary syndrome st-segment elevation mi clinical perspective ranolazine acknowledgments source coronary artery disease chronic coronary syndromes wilcoxon rank-sum test 5 clinical perspective kaplan-meier failure rates main content advertisement submit heart failure stroke red ™ aha double-blind clinical trial 1 discussion references 1 references international users arteriosclerosis tables 2 previous pdf early invasive strategy authors affiliations benjamin american journal article recently published conclusions— ranolazine st-elevation mi download pdf st-elevation acs class iii agents suppress arrhythmic activity dr gersh reports torsade de pointes core laboratory blinded local practice guidelines heart rhythm society prior heart failure low ejection fraction potential clinical relevance ��1-mm st depression chronic heart failure recurrent ischemic events complete heart block

Social Networks {👍}(10)

External Links {🔗}(226)

Analytics and Tracking {📊}

  • Google Analytics
  • Google Tag Manager

Libraries {📚}

  • Animate.css
  • Dropzone.js
  • Swiper
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Cookielaw

3.56s.